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Abstract
Background: Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal
growth factor receptor 2 (HER2) amplification occurs in approximately 13–23% of all GC cases and patients with HER2
overexpression exhibit a poor prognosis. Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, is an effective agent to
treat HER2-amplified breast cancer but it failed in gastric cancer (GC) clinical trials. However, the molecular mechanism
of lapatinib resistance in HER2-amplified GC is not well studied.
Methods: We employed an unbiased, genome-scale screening with pooled CRISPR library on HER2-amplified GC cell
lines to identify genes that are associated with resistance to lapatinib. To validate the candidate genes, we applied
in vitro and in vivo pharmacological tests to confirm the function of the target genes.
Results: We found that loss of function of CSK or PTEN conferred lapatinib resistance in HER2-amplified GC cell lines
NCI-N87 and OE19, respectively. Moreover, PI3K and MAPK signaling was significantly increased in CSK or PTEN null
cells. Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of
function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK
inhibitor trametinib.
Conclusions: Our study suggests that loss-of-function mutations of CSK and PTEN cause lapatinib resistance by re-
activating MAPK and PI3K pathways, and further proved these two pathways are druggable targets. Inhibiting the two
pathways synergistically are effective to overcome lapatinib resistance in HER2-amplified GC. This study provides
insights for understanding the resistant mechanism of HER2 targeted therapy and novel strategies that may ultimately
overcome resistance or limited efficacy of lapatinib treatment for subset of HER2 amplified GC.
Keywords: CRISPR/Cas9 screening, HER2 amplification, Lapatinib resistance, Gastric cancer, PI3K pathway, And MAPK
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Background
Gastric cancer (GC) is, worldwide, the fourth most com-
mon cancer and the second most common cause of
deaths of all malignancies [1, 2]. The American Cancer
Society estimated that there would be about 27,510 new
GC cases and 11,140 deaths from GC in the US during
2019 [3]. As an oncogenic driver, HER2 gene amplification
or HER2 oncoprotein overexpression occurs in approxi-
mately 13–23% of GC cases [4]. HER2 amplification and
overexpression are associated with poor prognosis in GC
patients [5, 6].
HER2 is transactivated through heterodimerization
with other HER family members. Notably, HER2 overex-
pression promotes tumor-cell proliferation, adhesion,
migration, and survival via constitutive activation of cas-
cades in the downstream signaling transduction of two
pathways: the Ras/Raf/Mitogen-activated protein kinase
(MAPK) pathway and the phosphatidylinositol 3 kinase
(PI3K)/AKT/mammalian target of rapamycin (mTOR)
pathway [7]. HER2-targeted therapies using trastuzumab,
a monoclonal antibody, and lapatinib, a small molecule
tyrosine kinase inhibitor, have been shown to be effect-
ive in treatment of breast cancer patients [8]. However,
clinical trial data of HER2-amplified GC have shown that
trastuzumab improved overall survival by only 2.7
months, and that lapatinib failed to improve survival in
HER2-positive GC patients [9–11]. These unsatisfactory
results can be attributed to the intrinsic or acquired re-
sistance to HER2-targeted therapy. To improve the effi-
cacy of HER2-targeted therapy in GC patients, there is
an urgent need to elucidate the mechanisms of resist-
ance. Previous studies have suggested that MET and
CCNE1 amplifications were involved in lapatinib resist-
ance, by compensating for HER2 via re-stimulation of
downstream signaling pathways [12, 13]. Further stud-
ies are needed to identify the mechanisms of resistance
for patients who do not carry those known genomic
alterations.
CRISPR-Cas9 gene editing-based library screening
using cell-based assays has been proven to be a very effi-
cient tool for screening for gene mutations that confer
drug resistance [14]. This approach is considered to be
superior to short hairpin RNA (shRNA) library screening
because of its robustness, and its higher specificity and
efficiency [15, 16]. To identify genomic alterations
potentially associated with lapatinib resistance, we
employed a gene-knockout screening approach using a
pooled genome-scale CRISPR-Cas9 knockout (GeCKO)
V2 library on two HER2-amplified GC cell lines. We
identified and validated a set of genes having loss-of-
function mutations that contribute to lapatinib resist-
ance. We also demonstrated that the lapatinib resistance
involves restoration of the PI3K/AKT and MAPK path-
ways, and that this restoration is induced by the loss of
function of either CSK or PTEN. Moreover, our study
shows that the resistance to lapatinib in these HER2-
amplified GC cells could potentially be overcome using
a combinational treatment with lapatinib; copanlisib, a
PI3K inhibitor; and trametinib, a MEK inhibitor. Our
findings not only reveal genes and signaling pathways
that contribute to lapatinib resistance, but also provides
a potential treatment strategy for a subset of HER2-
amplified GC.
Methods
Cell culture and reagents
Human GC cell lines (N87, OE19) were obtained from
the American Type Culture Collection (ATCC). All cell
lines were cultured in RPMI1640 medium (Life Tech-
nologies) with 10% FBS (Life Technologies), penicillin
(100 U/mL; Life Technologies), and streptomycin (100
U/mL; Life Technologies). All cells were maintained in a
humidified incubator with 5% CO2 at 37 °C. Drug treat-
ment reagents lapatinib, trastuzumab, LY294002, saraca-
tinib (AZD0530), rapamycin, trametinib (GSK1120212)
and copanlisib (BAY 80–6946), 5- FU were purchased
from Selleckchem.
CRISPR library gene knockout screening
The human GeCKO lentiviral pooled library lenti-
CRISPR v2 in one plasmid system was purchased from
Addgene (Cat # 1000000048) as two half-libraries (li-
brary A and library B). Genome-wide loss of function
screen using GeCKO library was carried out as described
[17]. Briefly, the library plasmid DNA was transformed
using electroporation method in Lucigen Endura electro-
competent cells (Lucigen). The grown colonies were re-
covered from the plates, followed by plasmid DNA
extraction using the Endotoxin-Free NucleoBond Xtra
Maxi Plus EF kit (Takara). For lentiviral transduction,
293FT cells were co-transfected with lentiCRISPRv2
half-library A or B vector DNA, pCMV-VSVg and
psPAX2 (Addgene) using Lipofectamine 2000 and PLUS
reagent (ThermoFisher Scientific). After 48 h, superna-
tants from the transfected 293FT cells were harvested
and concentrated using Lenti-X concentrator (Takara)
according to the manufacturer’s instructions. Pooled len-
tiviral libraries are transduced to 1 × 108 GC cells with
3 × 106 cells plated per transduction well. The multipli-
city of infection (MOI) is about 0.3 to ensure that most
cells receive only one stably integrated RNA guide. Puro-
mycin (1.5 μg/mL for OE19 cells and 0.75μg/ml for N87
cells) was added to the cells at 24 h post transduction
and maintained for 7 days. Baseline cells were harvested
after puromycin selection. Then transduced GC cells
were treated with lapatinib (1 uM for OE19 cells and 0.5
uM for N87 cells) or an equal volume DMSO for 14 days
and the survived cells were harvested. For each cell line,
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two separate infection replicates were performed. The
genomic DNA was extracted for PCR amplification and
deep sequencing of the genomic regions containing the
sgRNAs was conducted. The datasets generated and/or
analyzed during the current study are available in the
GEO repository (series accession number GSE148668),
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE148668].
Validation of candidate genes
For validation study, selected sgRNAs that target the can-
didate genes were individually synthesized and cloned into
the lentiCRISPR V2 plasmid (Addgene, #52961). Viral par-
ticles were generated as described above. Then N87 and
OE19 cells were infected with the corresponding viruses
and the lapatinib resistance was examined by treating the
cells with indicated doses of lapatinib for 6 days. Cell via-
bility assay was performed as described below at the end
of treatment.
Cell viability assay
For the cell viability assays, 4000 cells/each well in a 96-
well plate were treated with indicated drugs for 6 days
and cell viabilities were measured using the CellTiter-
Glo® luminescent cell viability assay kit according to the
manufacturer’s instructions (Promega). The lumines-
cence intensity was measured using a multi-label plate
reader (SpectraMax M5, Molecular Devices). The cell
viabilities were calculated as relative values compared to
the untreated controls.
Western blotting
After indicated treatment, cells were harvested and lysed
with RIPA lysis buffer (Thermofisher Scientific) supple-
mented by protease inhibitor/phosphatase inhibitor cock-
tails (Cell signaling Technology). Lysates were separated
on NuPAGE™ 4–12% Bis-Tris protein gels (Invitrogen)
and were transferred to PVDF membranes (Millipore).
The membranes were blocked with 5% fat-free milk (Cell
signaling Technology) dissolved in TBST buffer (50mM
Tris-HCl, 150mM NaCl, 0.1% Tween-20). Then, the
membranes were incubated with primary antibodies over-
night at 4 °C. CSK antibody (#4980), PTEN antibody
(#9188), MAPK1/2 antibody (#9102), Phospho-MAPK1/2
(Thr202/Tyr204) antibody (#4370), Phospho-AKT
(Ser473) antibody (#9271), AKT antibody (#9272) were
purchased from Cell Signaling Technologies. GAPDH
antibody (FL-335) was obtained from Santa Cruz biotech-
nology and horseradish peroxidase-conjugated secondary
antibodies (anti-rabbit: NA934V, anti-mouse: NA931V)
were purchased from GE healthcare. SuperSignal West
Pico Chemiluminescent Substrate (Pierce) was used to de-
tect signals.
Caspase-Glo 3/7 apoptosis assay
Caspase activity was detected by using Caspase-Glo 3/7
assay kit (Promega). Briefly, The GC cells were seeded in
96-well white luminometer assay plates at a density of
4000 cells per well and incubated at 37 °C. Cells were
treated with either lapatinib or vehicle for 48 h. 100ul
caspase 3/7 reagents were added to each well and incu-
bated for 1 h on rotary shaker at room temperature. The
luminescence intensity was measured using a multi-label
plate reader (SpectraMax M5, Molecular Devices).
In vivo pharmacological assessment with xenograft
model
All procedures are performed in the biosafety cabinet in
the Biosafety Label 2 (BSL2) procedure room of the
animal facility at UConn Health. All work follows the
animal protocols approved by both the Institutional
Animal Care and Use Committee (IACUC) of UConn
Health and The Jackson Laboratory (#101899–0921 and
#101660–0920, respectively) and carried out in accord-
ance with the NIH Guide for the Care and Use of
Laboratory Animals. Furthermore, this manuscript ad-
heres to the ARRIVE Guidelines for reporting animal
research. Six-to-seven-week-old female NOD/SCID/IL-
2γ-receptor null (NSG) mice were purchased from the
Jackson laboratory (Bar Harbor, ME, stock number
005557). Mice were maintained on a 12-h light/12-h
dark cycle at a controlled temperature of 22–23 °C.
Water and standard mouse food were freely available.
The initial body weight of the animals at the time of ar-
rival was between 19 and 22 g. Mice were allowed to
acclimatize to local conditions for 1 week before being
injected with tumor cells. Xenografts bearing N87-WT,
N87-CSK−/− or N87-PTEN−/− tumors were induced by
injecting wild type N87, CSK or PTEN null N87 cells
(5 × 106 per mouse) subcutaneously into the right flank
of mice, respectively. The tumors were then measured
twice a week using calipers, and the tumor volume in
mm3 was calculated according to the following formula:
(width2 × length)/2. Drug treatment was initiated when
tumors reached a volume of 150–250 mm3. Mice were
randomly divided into seven treatment groups consisting
of 8–10 mice in each group: 1) vehicle only, 2) lapatinib
only, 3) lapatinib plus trametinib, 4) lapatinib plus
copanlisib, 5) trametinib plus copanlisib, 6) lapatinib
plus trametinib plus copanlisib, 7) 5-FU. Lapatinib were
administered via oral gavage at a concentration of 100
mg/kg in 2% DMSO, 30% polyethylene glycol (PEG) 300
(Sigma), 5% Tween 80 (Sigma) in sterile Milli-Q water
Monday through Friday. A dose of 50 mg/kg of 5-FU in
was given intraperitoneally once weekly. Trametinib
were administered by oral gavage at concentration of
0.3 mg/kg in 30% PEG400 and 0.5% DMSO in sterile
Milli-Q water Monday through Friday. Copanlisib were
Ning et al. BMC Cancer          (2021) 21:923 Page 3 of 17
administered by intravenous injection at the dose of 1
mg/kg in 20% PEG 400/ acidified water (0.1 N HC, pH
3.5) three times weekly. After 21 days of treatment, the
animals were euthanized using a CO2 chamber in
accordance with the recommendation of the Panel on
Euthanasia of the American Veterinary Medical Associ-
ation, and the tumors were collected from each mouse
to measure the weight. Results are presented as mean
volumes or weights for each group. Error bars represent
the SD of the mean. Statistical calculations were per-
formed using Prism 8 (GraphPad). Statistical analysis to
compare tumor volumes in xenograft-bearing mice was
performed with 2-way ANOVA. Differences between
two groups of tumor mass were assessed by an unpaired
Student’s t-test. Differences between groups were con-
sidered statistically significant if p value < 0.05.
CRISPR library data processing and initial analysis
Raw FASTQ files were trimmed using customized
scripts. To align the processed reads to the library, the
designed sgRNA library sequences were assembled into
a Burrows-Wheeler index using the Bowtie build-index
function [18]. The qualities of fastq files are evaluated
using fastqc with options “-Q33 -q 25 -p 50”. Then high
quality reads are mapped to the screening library with <
2 bp mismatches using Bowtie, and the raw read counts
of sgRNAs from all samples were merged into a count
matrix. Next the effects of gene knockout were estimated
using three different algorithms: Model-based Analysis of
Genome-wide CRISPR-Cas9 Knockout (MAGeCK) Robust
Rank Aggregation (RRA) [19], MAGeCK MLE [20] and
edgeR algorithms (Fig. S1A) [21]. MAGeCK RRA algorithm
builds a mean-variance model to estimate the variance of
the read counts, and uses these variance estimations to
model the read count changes for each sgRNA in the treat-
ment samples relative to the control samples. The read
count changes (sgRNA scores) of all sgRNAs targeting each
gene are then ranked and summarized into one score for
the gene (gene score), using a modified RRA algorithm.
MAeCK MLE initially use the raw table of reads as input,
and models the read count of each sgRNA for each sample
by a negative binomial random variable and estimates the
essentiality of genes in a CRISPR screen via a maximum
likelihood approach. The edgeR algorithm uses high-
throughtput sequencing counts to detect significantly se-
lected sgRNAs and genes by negative binomial method.
RNAseq and data analysis
Total RNA was extracted from indicated GC cell lines
using RNeasy mini kit (Qiagen). mRNA-Seq libraries for
the Illumina Novaseq platform were generated and se-
quenced at Novogene (California, USA). For the RNAseq
raw sequencing reads, we used HISAT2 version 2.2.0
[22] to generate indexes and to map reads to the human
genome assembly GRCh37 (hg19). For assembly, we
chose SAMtools version 1.7 [23] and the HTSeq version
0.9.1 [24] as the gene-level read counts could provide
more flexibility in the differential expression analysis.
Both HISAT2 and HTSeq analyses were conducted
using the high-performance research computing re-
sources provided by Jackson Laboratory for Genomic
Medicine in the Linux operating system. Differential ex-
pression and statistical analysis were performed using
DESeq2 (release 3.7) in RStudio (version 1.1.447). We
used variance stabilizing transformation to account for
differences in sequencing depth. P-values were adjusted
for multiple testing using the Benjamini-Hochberg pro-
cedure. A false discovery rate (FDR) adjusted p-value <
0.05 was set for the selection of DEGs, with differential
expression defined as |log2 (ratio)| ≥ 0.585 (± 1.5-fold)
with the FDR set to 5%. Genes were sorted according to
their log2-transformed fold-change values after shrink-
age in DESeq2 and used for gene set enrichment analysis
(GSEA) [25]. Significant gene sets were used to perform
the leading-edge analysis. We detected clusters of path-
ways that shared many leading-edge genes using a com-
munity detection algorithm and manually curated these
clusters to elucidate the important phenotype-associated
pathway groups visualized on the bar plots. Pathway
analysis was conducted with the Kyoto Encyclopedia of
Genes and Genomes (KEGG) collection of online data-
bases dealing with genomes, enzymatic pathways, and
biological chemicals [26].
Whole exome sequencing (WES) data analysis
For the 103 GC samples in previous publication [27], we
downloaded the raw reads from European Nucleotide
Archive with accession number PRJEB10531. For the
variant analysis using WES data, all sequencing reads
were submitted to a quality control check using FASTX-
Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). The
phred value 20 was chosen as the minimum threshold
for base quality. Following is the alignment of resulting
reads to hg19 reference genome with Burrows-Wheeler
Aligner (BWA) [28] and Picard (http://broadinstitute.
github.io/picard/) was applied for post-alignment proce-
dures as sorting, indexing, and marking duplicates. The
alignments were submitted to local realignment around
INDELs and base quality score recalibration by using the
Genome Analysis Toolkit (GATK) version 3.5. Single nu-
cleotide variants (SNVs) were identified using MuTect2
on the pre-processed sequencing data with default param-
eters. For Copy Number Variants (CNVs), the XHMM
(eXome-Hidden Markov Model) [29] C++ software was
run to detection CNVs from exome sequencing data.
XHMM includes several key steps in running depth of
coverage calculations, data normalization, CNV calling,
and statistical genotyping and involves a number of
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parameters. In our study, we set all parameters to default
(minTargetSize: 10; maxTargetSize: 10,000; minMeanTar-
getRD: 10; maxMeanTargetRD: 500; minMeanSampleRD:
25; maxMeanSampleRD: 200; maxSdSampleRD: 150) for
filtering samples and targets, and prepared the data for
normalization via XHMM.
Statistical analysis
Statistical calculations were performed using Prism 8
(GraphPad). Differences between two variables were
assessed by an unpaired Student’s t test. An observation
was considered significant if the p-value was less than
0.05.
Results
CRISPR library screening identifies candidate genes with
loss of function that confers lapatinib resistance in HER2-
amplified GC cells
To identify genes with loss of function that confers drug
resistance to lapatinib, we performed a genome-wide
CRISPR/Cas9 gene knockout screening in two human
GC cell lines harboring HER2 amplification: N87 and
OE19. As shown in Fig. 1a, a pooled GeCKO V2 library
was amplified for lentivirus production, and then two
biological replicates of N87 cells, and two of OE19 cells,
were transduced with the lentivirus-containing GeCKO
V2 library at a multiplicity of infection (MOI) of 0.3.
Puromycin selection was performed before lapatinib
treatment on each cell line to enrich successfully trans-
duced cells. After 14 days of lapatinib treatment, the
drug-treated and vehicle-treated cells were harvested.
Genomic DNA was extracted for PCR amplification and
subsequent deep sequencing of the regions containing
single-guide RNAs (sgRNAs).
The deep sequencing data showed that the sgRNA dis-
tribution in the lapatinib-treated cells was significantly
different from that in the vehicle-treated cells, for both
the N87 and OE19 cell lines (Wilcoxon rank-sum test,
p-value < 2.2e-16) (Fig. 1b). The replicates of lapatinib-
treated cells are clustered separately from the replicates
of cells under other conditions, and all replicates within
samples are highly correlated (Pearson correlation coeffi-
cient > 0.9) (Fig. S1C), indicating the consistency of our
screening system. In addition, we found enrichment of
some sgRNAs in the lapatinib-treated cells, by determin-
ing, for each sgRNA, the difference in the read count be-
tween the lapatinib-treatment samples and the control
samples. After 14 days of lapatinib treatment, 694
sgRNAs and three sgRNAs showed greater than 20-fold
and 100-fold enrichment, respectively, in the N87 group;
and 357 sgRNAs and 34 sgRNAs showed greater than
20-fold and 100-fold enrichment, respectively, in the
OE19 group (Table S1 and S2). A panel of candidate
genes were detected from this screening using three
different algorithms, MAGeCK-RRA, MAGeCK-MLE,
and edgeR (Table S3 and S4), and the genes showing the
greatest enrichment included CSK, BAX, KEAP1,
PRR24, TADA1, KCTD5, PTEN and NF1 which are
highlighted shown in Fig. 1c. Our data indicate that loss
of these particular genes may contribute to lapatinib
resistance.
In vitro validation study confirms that loss of function of
CSK, PTEN, and other candidate genes confers resistance
to lapatinib
After identifying candidate genes from the screening de-
scribed above, we performed validation experiments with
selected genes to confirm whether or not their loss of
function confers lapatinib resistance in GC cells. The
genes selected for validation include: 1) genes that were
identified as among the top 20 candidates by at least two
of the three algorithms (MAGeCK-RRA, MAGeCK-
MLE, and edgeR); and 2) genes that were identified as
among the top 20 candidates in both N87 and OE19
cells. The genes selected using these criteria are
highlighted in gray in Tables S3 and S4. For each gene
selected for validation, we selected two sgRNAs targeting
that gene. Then, for each gene-targeting sgRNA, N87
and OE19 cells were infected with lentivirus carrying
that sgRNA and were then treated with different doses
of lapatinib for six days. After treatment, drug resistance
was assessed by determining cell viability. CSK, PTEN,
KCTD5, MED24, KEAP1, NF1, BAX, TADA1 and KRAS
were validated to confer resistance (p < 0.05, Tables S3
and S4; validated genes are shown in red). While signifi-
cant resistance to lapatinib was validated in OE19 cells
with loss of function of BAX, KEAP1, NF1, and TADA1,
and in N87 cells with loss of function of NF1 and
KCTD5, (Fig. S2A and Fig. S2B), our data show that loss
of CSK or PTEN in N87 and OE19 cells (confirmed by
western blotting) conferred the most significant resist-
ance to lapatinib treatment (OE19 validation groups,
two-way ANOVA, ****, P < 0.0001, n = 3 replicates; N87
validation groups, two-way ANOVA, ***, P < 0.001, n = 3
replicates) (Fig. 2a and b). Both CSK and PTEN are
tumor-suppressor genes. CSK is a non-receptor protein
tyrosine kinase that serves as an indispensable negative
regulator of the Src family tyrosine kinases (SFKs). In-
duction of signaling pathways such as STAT3 or PI3K
pathway via up-regulation of SRC signaling has been
linked to cancer progression [30]. PTEN is a protein
tyrosine phosphatase that negatively regulates the PI3K/
AKT pathway to repress tumor-cell growth and survival.
Because loss of CSK or PTEN exhibited the most signifi-
cant resistance to lapatinib in both N87 and OE19 cells,
we subsequently focused on characterization of CSK-
null and PTEN-null cells in this study.
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We examined apoptosis induced by lapatinib treat-
ment in CSK- and PTEN-null cells as well as in control
cells (cells transduced with non-targeting sgRNA, and
cells treated with vehicle) by measuring caspase-3/7 acti-
vation (Caspase-Glo 3/7 assay). Consistent with our cell
viability results, OE19 cells and N87 cells deficient for
CSK or PTEN showed significantly lower levels of apop-
tosis compared to control cells. OE19 cells transduced
with non-targeting sgRNA showed 3.79 ± 0.16-fold
greater levels of caspase-3/7 activity compared with
Fig. 1 Genome-sale CRISPR library knockout screening for genes associated with lapatinib resistance in GC cell lines. a Schematic diagram of the
CRISPR library screening strategy. The loss of function screening was performed with the infection of pooled lentivirus containing the GeCKO
library V2.0 on N87 and OE19 cells, followed by puromycin selection and lapatinib treatment. The cells were harvested for genomic DNA to PCR
the sgRNAs and the subsequent sequencing after 14 days post treatment. b The distribution of sgRNA frequencies in the untreated (baseline), the
vehicle-treated (DMSO), and lapatinib-treated N87 and OE19 cells, respectively. c Scatterplot showing identification of top 10 candidate genes
using Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK). Wilcoxon rank-sum test indicated the following, **significant
difference from the control, p < 2.2e-16
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vehicle-treated OE19 cells, while CSK- and PTEN-null
OE19 cells showed 1.55 ± 0.16-fold and 1.50 ± 0.10-fold
greater levels of caspase-3/7 activity, respectively,
compared to control cells (control vs CSK-sgRNA, con-
trol vs PTEN-sgRNA, unpaired t test: p < 0.001)
(Fig. 2c). Experiments using CSK- or PTEN-null N87
Fig. 2 Functional validation of CSK or PTEN null N87 and OE19 cells. a Cell viability of CSK or PTEN knockout OE19 cells treated with indicated
doses of lapatinib. OE19 cells were transduced with lentiviruses carrying sgRNAs targeting CSK, PTEN, or non-targeting control sgRNA. The drug
resistance of the cells from each group was measured by calculating the relative percentage of cell viability. CSK or PTEN protein expressions
were evaluated by western blotting. b Cell viability of CSK or PTEN knockout N87 cells treated with different doses of lapatinib. N87 cells
transduced with non-targeting sgRNA as control. Shift between control cells and gene knockout cells in the dose response curve displays the
reduced sensitivity to lapatinib in the GC cell lines. CSK or PTEN protein expressions were evaluated by western blotting. c Caspase-Glo 3/7 assay
analysis to examine lapatinib induced caspase-3/7 activity after 48 h treatment in CSK or PTEN null cells OE19 and N87 cells. OE19 or N87 cells
transduced with virus carrying non-targeting sgRNA as control. Unpaired Student’s t test indicated the following: *significant difference from the
control, p < 0.05; **significant difference from the control, p < 0.01
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cells showed similar results (control vs CSK-sgRNA,
unpaired t test: P < 0.001; control vs PTEN-sgRNA,
unpaired t test: P < 0.01) (Fig. 2c). Together, these re-
sults indicate that loss of function of CSK or PTEN
significantly inhibits lapatinib-induced apoptosis.
Up-regulation of PI3K and MAPK signaling was observed
in CSK-null and PTEN-null GC cells
The similar resistance phenotypes of CSK and PTEN
knockout cells suggest that these two genes might be
functionally linked. To further understand whether there
is a functional interaction between CSK and PTEN, we
analyzed the interaction networks between the two pro-
teins using Search Tool for the Retrieval of Interacting
Genes (STRING) [31]. The networks established by
interacting proteins are helpful in elucidating potential
molecular mechanisms, including functionally related
proteins within the networks, underlying lapatinib resist-
ance in HER2-amplified GC cells. Here, our STRING
analysis suggests that CSK, PTEN, and ERBB2 (HER2)
are functionally linked (Fig. 3a), and PI3K/AKT pathway
components PIK3CA, AKT1, PIK3CG, PIK3CB, and
PIK3CD are predicted as directly linked functional part-
ners of the three functionally linked proteins (Fig. 3b),
indicating that CSK and PTEN are involved in HER2 sig-
naling and in the PI3K/AKT pathway in GC cells. To
better understand the molecular mechanisms of lapati-
nib resistance in CSK-null and PTEN-null GC cells, we
performed RNA-Seq on CSK-null and PTEN-null cells
and the corresponding parental cells and compared their
transcriptome profiles. The differentially expressed genes
(DEGs) are shown in heat maps (Fig. S3C and S3D). A
total of 139 genes were identified as significant DEGs
between CSK-null cells and parental (N87) cells, and
997 genes were identified as significant DEGs between
PTEN-null cells and parental (OE19) cells (for all signifi-
cant DEGs, fold change > 1.5, FDR < 0.1). The data also
suggests that, in GC cells, a mutation resulting in loss of
PTEN function has a much greater impact on the gene
expression profile compared to a mutation resulting in
loss of CSK function. To provide insight into the cellular
pathways associated with CSK and PTEN, we performed
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis of the DEGs. Among the pathways
identified as enriched (Fig. 3c and d), the MAPK, PI3K,
and Wnt pathways were enriched in both CSK- and
PTEN-null GC cells (> 1.5-fold enrichment), suggesting
that these pathways play important roles in lapatinib
resistance.
Considering that PI3K and MAPK are the major
downstream pathways of the HER2 receptor, we hypoth-
esized that loss of CSK or PTEN function would restore
the PI3K/AKT and/or MAPK signaling pathways, result-
ing in resistance to lapatinib. To test this, we examined
the phosphorylation levels of AKT and MAPK in CSK-
null and PTEN-null GC cells, using western blotting, fol-
lowing treatment of the cells with lapatinib. Consistent
with the results of our protein interaction and pathway
analyses, we found that, following treatment of OE19
cells with 0.05 μM lapatinib, the phosphorylation levels
of AKT and MAPK were substantially higher in CSK-
and PTEN-null cells than in the control cells (Fig. 3e).
Treatment of N87 cells with 0.01 μM lapatinib yielded a
similar pattern of AKT phosphorylation in CSK- and
PTEN-null cells compared to the control cells, but the
phosphorylation levels of MAPK appear to show little or
no difference between, on the one hand, the CSK- or
PTEN-null cells, and, on the other, the control cells
(Fig. 3f). To determine whether expression of PTEN is
dependent on CSK expression, and vice versa, we
assessed PTEN expression in CSK knockout OE19 and
N87 cells, and CSK expression in PTEN knockout OE19
and N87 cells, by western blotting. Results showed no
significant change in expression of either gene as a result
of knockout of the other, in either cell line (Fig. 3g and
h), suggesting that neither CSK nor PTEN regulates the
protein expression of the other.
Pharmacological inhibition of the PI3K and MAPK
pathways synergistically overcomes the resistance to
lapatinib in CSK-null and PTEN-null GC cells
Trastuzumab is a potent anti-HER2 agent and is usually
applied with or without lapatinib in HER2-amplified
breast cancer patients. In addition, a trastuzumab-based
treatment has been approved by the FDA as a target
treatment for HER2-positive advanced GC [32]. Here,
we tested whether loss of CSK or PTEN in GC cells con-
fers resistance to combined trastuzumab and lapatinib
treatment. We observed that CSK-null and PTEN-null
OE19 cells were significantly more resistant than control
cells to combined lapatinib (0.05 μM) and trastuzumab
(0.1–10mg/ml) treatment (Fig. 4a). Similar results were
obtained in CSK-null and PTEN-null N87 cells (Fig.
S4A), indicating that loss of function of CSK or PTEN
confers resistance to both lapatinib and trastuzumab in
HER2-amplified GC cells.
To further test our hypothesis that re-activation of the
signaling downstream of HER2 is the mechanism under-
lying the lapatinib resistance, we employed a pharmaco-
logical approach to modulate the PI3K/AKT/mTOR,
MAPK, and SRC signaling pathways. Because CSK nega-
tively regulates SRC signaling, we first treated CSK-null
and PTEN-null OE19 cells with the SRC family kinase
inhibitor AZD0530 (saracatinib). As shown in Fig. 4b,
AZD0530 (0.01–1 μM) in combination with 0.05 uM
lapatinib, decreased the cell viability of CSK- and PTEN-
null OE19 cells in a dose-dependent manner, indicating
that re-activation of the SRC signaling pathway in both
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Fig. 3 Protein interaction network prediction, gene expression profile and pathway analysis of CSK or PTEN knockout cell lines and Up-regulation of PI3K/
AKT and MAPK pathways in the CSK or PTEN knockout GC cells. Protein interaction network (a) and the predicted partners (b) were analyzed by STRING.
CSK, PTEN and HER2 (ERBB2) were mapped by searching the STRING database version 10.5. In the resulting protein association network, proteins are
presented as nodes which are connected by lines whose thickness represents the confidence level. (c) The bar plot depicts the enriched pathway among
the DEGs between CSK null cells (N87-CSK-sgRNA) and parental N87 cells (N87) by KEGG pathway analysis. d The bar plot depicts the enriched pathway
among the DEGs between PTEN null cells (OE19-PTEN-sgRNA) and parental OE19 cells (OE19) by KEGG pathway analysis. e The levels of phosphorylated
and total proteins of AKT and MAPK were assessed by western blotting in CSK or PTEN knockout OE19 cells after treating with 0.05 uM lapatinib,
respectively. OE19 cells transduced with non-targeting sgRNA as control. f The levels of phosphorylated and total proteins of AKT and MAPK were assessed
by western blots in CSK or PTEN knockout N87 cells after treating with 0.01 um lapatinib, respectively. N87 cells transduced with non-targeting sgRNA as
control. g PTEN and CSK protein expression was examined by western blotting in CSK knockout OE19 cell lines and PTEN knockout OE19 cell lines,
respectively. OE19 cells transduced with non-targeting sgRNA as control. h PTEN protein and CSK protein expression was examined by western blotting in
CSK knockout N87 cell lines and PTEN knockout N87 cell lines, respectively. N87 cells transduced with non-targeting sgRNA as control
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CSK- and PTEN-null OE19 cells may confer the resist-
ance to lapatinib. However, at the highest dose of
AZD0530 (1 μM), the percentage of PTEN-null cells that
survived the treatment was significantly larger than the
percentage of CSK-null cells that survived (42.49 ± 2.54%
of PTEN-null cells versus 9.15 ± 0.88% of CSK-null cells,
Fig. 4b), suggesting that SRC signaling is the major re-
activated pathway in the CSK-null OE19 cells but not in
the PTEN-null OE19 cells. We also treated the CSK-
and PTEN-null OE19 cells with the PI3K inhibitor
copanlisib (BAY 80–6946), a drug approved by the FDA
for patients with relapsed follicular lymphoma [33]. Re-
markably, copanlisib (0.01–1 μM) in combination with
0.05 μM lapatinib inhibited the growth of CSK- and
PTEN-null OE19 cells as well as control cells in a dose-
dependent manner (Fig. 4c), and similar results were ob-
tained with another PI3K inhibitor, LY294002 (Fig. S4B),
indicating that the PI3K pathway plays an important role
in lapatinib resistance of CSK- and PTEN-null GC cells.
Because mTOR is a key molecule downstream of the
PI3K pathway that regulates cell growth, proliferation,
and survival, we tested whether an mTOR inhibitor,
Fig. 4 Pharmacological inhibition of PI3K, MAPK and SRC signaling pathways re-sensitizes resistant GC cells to lapatinib. OE19 cells transduced
with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a
Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of trastuzumab for 6 days. b Growth curve of test groups
treated with indicated dose of SRC inhibitor AZD0530 for 6 days. c Growth curve of test group treated with 0.05 μM lapatinib in combination
with indicated dose of PI3K inhibitor copanlisib for 6 days. d Growth curve of test groups treated with 0.05 μM lapatinib in combination with
different doses of mTOR inhibitor rapamycin for 6 days. e Growth curve of test groups treated with 0.05 μM lapatinib in combination with
different doses of MEK inhibitor trametinib for 6 days. f Inhibition effect of 0.05 μM lapatinib alone or in combination with 0.1 μM trametinib or
/and 0.1 μM copanlisib for 6 days. Unpaired Student’s t test indicated the following: *significant difference from the control, p < 0.05; **significant
difference from the control, p < 0.01
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rapamycin, could overcome the lapatinib resistance in
CSK-null and PTEN-null GC cells. We found that rapa-
mycin (0.01 μM) in combination with lapatinib (0.05
uM) significantly inhibited growth of CSK- and PTEN-
null OE19 cells as well as of control cells (Fig. 4d). How-
ever, increased doses of rapamycin (0.025–0.05 μM) with
0.05 uM lapatinib did not further decrease cell growth
(Fig. 4d), suggesting that mTOR may contribute only
partially to lapatinib resistance in the GC cells. In
addition, we treated CSK- and PTEN-null OE19 cells
with lapatinib and the MAPK inhibitor trametinib
(GSK1120212), a drug approved by the FDA in combin-
ation with dabrafenib for treatment of patients with
BRAF V600E/K-mutant metastatic melanoma [34]. In
our pharmacological test, we observed that trametinib
(0.01–1 μM) in combination with 0.05 μM lapatinib dra-
matically overcame the resistance to lapatinib in the
CSK- and PTEN-null OE19 cells in a dose-dependent
manner (Fig. 4e), indicating that re-activation of the
MAPK pathway in CSK- and PTEN-null OE19 cells may
also play an important role in lapatinib resistance.
While the combination of lapatinib plus copanlisib or
lapatinib plus trametinib could significantly inhibit the
lapatinib resistance in the CSK or PTEN null OE19 cells,
it requests high dose of drugs (1 μM copanlisib or 1 uM
trametinib) to overcome the resistance (Fig. 4c and e).
Therefore, we tested another treatment strategy using
three drugs combination of lapatinib, copanlisib and tra-
metinib with relative low doses. As shown in Fig. 4f,
lapatinib alone didn’t inhibit the growth of CSK or
PTEN null OE19 cells, whereas lapatinib plus 0.1 μM
copanlisib or lapatinib plus 0.1 μM trametinib signifi-
cantly inhibited the cell growth, but not completely.
When the cells were treated with a combination of these
three agents (i.e. 0.05 μM lapatinib, 0.1 μM copanlisib,
and 0.1 μM trametinib), the cell viability dramatically de-
creased to 0.22 ± 0.08% in CSK null OE19 cells and
7.65 ± 0.31% in the PTEN null OE19 cells, respectively.
It almost completely overcame the lapatinib resistance.
Similar result was presented in CSK or PTEN null N87
cells (Fig. S4C). This finding further supports that re-
activation of PI3K and MAPK are both involved in lapa-
tinib resistance in HER2-amplified GC with loss of func-
tion of CSK or PTEN. Thus, our study provides a
potential therapeutic strategy for the GC patients of
HER2 amplification with CSK or/and PTEN loss of func-
tion mutation.
In vivo pharmacological assessment confirms the efficacy
of the new therapeutic strategy
To further validate the efficacy of the drug combination
of lapatinib, copanlisib and trametinib, we applied it to
in vivo xenograft model for pharmacological assessment
(Fig. 5a). Firstly, we did lapatinib dosing test with
xenograft models bearing N87-WT, N87-CSK−/− and
N87-PTEN−/− tumors, and found that N87-WT tumors
grow relatively slow and it is sensitive to lapatinib treat-
ment (vehicle vs lapatinib 50 mg/kg, 2-way ANOVA: ***,
P = 0.0009). N87-CSK−/− and N87-PTEN−/− tumors
grow much faster and form big tumor masses after 3
weeks. Comparing with N87-WT tumors, N87-CSK−/−
tumors are relatively insensitive to lapatinib (vehicle vs
lapatinib 100 mg/kg, 2-way ANOVA: ns, P = 0.0924) and
N87-PTEN−/− tumors are resistant to lapatinib treat-
ment (vehicle vs lapatinib 200mg/kg, 2-way ANOVA:
ns, P = 0.1607) (Fig. S5). In the second experiment, we
compared the efficacy of the drug combinations: lapati-
nib plus trametinib plus copanlisib and other treatment
conditions including gastric cancer standard chemother-
apy agent fluorouracil (5-FU). Since N87-WT is sensitive
to lapatinib treatment, we exclude it in the drug combin-
ation treatment. From the in vivo test with N87-
PTEN−/− xenograft tumor, a significant effect upon
tumor growth was observed with combination of lapati-
nib, trametinib and copanlisib when compared with ve-
hicle (2-way ANOVA: ****, P < 0.0001), lapatinib alone
(2-way ANOVA: ***, P = 0.0002), 5-FU treatment group
(2-way ANOVA: **, P = 0.0097), lapatinib plus copanlisib
(2-way ANOVA: **, P = 0.0067), trametinib plus copanli-
sib (2-way ANOVA: ****, P < 0.0001), respectively
(Fig. 5b). Similarly, when the mass of the tumors at end-
point were compared, the three drugs combination
showed significant improvement over all other groups
(Unpaired t-test: P < 0.05) (Fig. 5b). Similar result was
obtained from the experiment with N87-CSK−/− xeno-
graft (Fig. 5c), except trametinib and copanlisib in the
three drug combinations showed synergistic effects in
xenografts bearing N87-PTEN−/− but not N87-
CSK−/−, indicating the three drugs combination tends
to be more effective on more resistant tumors. Over-
all, the in vivo drug treatment study further suggests
that synergistically inhibiting PI3K and MAPK path-
ways can significantly inhibit tumor growth in those
lapatinib resistant tumors with loss of function muta-
tions of CSK or PTEN.
Discussion
Molecular targeted therapy has shown great specificity
in eliminating malignant cells with minimal side effects
in cancer therapy compared with conventional chemo-
therapy [35]. Lapatinib, a dual EGFR and HER2 inhibi-
tor, are clinically effective against HER2-amplified breast
cancer by blocking HER2 phosphorylation, resulting in
inhibition of downstream PI3K/AKT and MAPK path-
ways [36]. However, it didn’t improve survival signifi-
cantly in clinical trials of HER2-amplified gastric cancer
(GC), indicating additional oncogenic alterations or the
specific tumor microenvironment could contribute to
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the drug resistance in GC. The previous studies in GC
suggest that signaling through other receptor tyrosine ki-
nases (RTKs), such as amplification of MET, IGFR, and
HER3 confer anti-HER2 treatment resistance by re-
stimulating downstream of PI3K and MAPK signal
transduction, thus bypassing the inhibitory effect of
Fig. 5 In vivo antitumor efficacy of combination of lapatinib, trametinib and copanlisib comparing with other treatment conditions including
vehicle, lapatinib (100 mg/kg), lapatinib plus trametinib (0.3 mg/kg), lapatinib plus copanlisib (1 mg/kg), trametinib plus copanlisib, and 5-FU (50
mg/kg). Tumor volumes of these xenografts are shown on the left and their tumor mass after 3 weeks of treatment are shown on the right. a A
schematic diagram for in vivo drug treatment experiment with mouse xenograft model. b The synergistic effect of trametinib, copanlisib and
lapatinib in N87-PTEN−/− gastric cancer xenograft model comparing with other treatment conditions. Tumor sizes were measured twice a week
and tumor masses were measured at the end of experiment. Tumor volume and mass were presented as mean. Error bars, SD. c The antitumor
effect of trametinib, copanlisib and lapatinib in N87-CSK−/− gastric cancer xenograft model comparing with other treatment conditions. Tumor
sizes were measured twice a week and tumor masses were measured at the end of experiment. Tumor volume and mass were presented as
mean. Error bars, SD. Unpaired Student’s t test indicated the following: *significant difference between the indicated two groups, p < 0.05;
**significant difference between the indicated two groups, p < 0.01
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lapatinib or trastuzumab [37, 38]. In our CRISPR/Cas9
based genome-wide knockout screening study, we iden-
tified and demonstrated that loss of function mutations
of CSK or PTEN conferred resistance to lapatinib in
HER2-amplified GC cell lines by restoring downstream
PI3K and MAPK pathways of HER2 receptor. Interest-
ingly, a previous study in breast cancer suggests that in-
creased SRC kinases activates the PI3K signaling cascade
via altering the capacity of the PTEN C2 domain binding
to the cellular membranes rather than directly interfer-
ing with PTEN enzymatic activity [39]. Combining with
our observation, it indicates CSK, the SRC family kinases
negative regulator, functionally linked with PTEN in
regulating PI3K signaling in lapatinib resistance, which
explained the similar resistance phenotype of CSK and
PTEN null GC cells and stable PTEN protein level in
CSK null cells in our study (Fig. 2 and Fig. 3e-h). In
addition, our result is consistent with the previous study
in breast cancer that loss of function of PTEN triggered
hyperactivation of the MAPK pathway [40]. Taken to-
gether, our data suggest that loss of function mutation
of CSK or PTEN leads to the up-regulation and
Fig. 6 A schematic diagram showing potential HER2-related signaling pathways and action mechanisms of various inhibitors in HER2-amplified
GC. Heterodimerization of HER2 with other HER family members (such as EGFR, HER3, HER4) result in tyrosine kinase activation with the
subsequent signaling cascade, including members of MAPK and PI3K/AKT/mTOR pathways. As a result of these signaling pathways activation,
different nuclear factors are recruited and modulate the transcription of different genes involved in cell-cycle progression, proliferation, and
survival. Trastuzumab inhibits HER2 by targeting its extracellular domain, whereas lapatinib inhibits both HER2 and EGFR by inhibiting the
intracellular tyrosine kinases. HER2 targeted therapy could be interrupted by re-activation MAPK and PI3K/AKT/mTOR pathways by compensatory
activation of MET, IGF-RI, HER3 or loss of function mutations of tumor suppressor genes such as CSK, PTEN, NF1. In addition, drug resistance could
be conferred by loss of function mutations of downstream genes such as KEAP1 and BAX by dysregulation of cellular antioxidants, xenobiotic
detoxification enzymes and apoptosis, respectively. Lapatinib combining with lapatinib, SRC inhibitor AZD0530, PI3K inhibitor copanlisib, mTOR
inhibitor rapamycin or MEK inhibitor trametinib could counteract the resistance at different level, respectively. A combinational treatment strategy
with lapatinib, copanlisib and trametinib is demonstrated more effective for HER2 amplified GC with CSK, PTEN, NF1and KEAP1 mutations in
this study
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hyperactivation of PI3K and MAPK pathways, which
could be the central mechanism for lapatinib resistance
in these GC cells.
Furthermore, our in vitro and in vivo pharmacological
study showed significant synergistic effect of PI3K in-
hibitor copanlisib and MEK inhibitor trametinib to in-
hibit resistant GC tumor growth when they are
combined with lapatinib (Figs. 4 and 5). This finding
could be potentially important for developing novel anti-
HER2 therapy. In particular, HER2-amplified GC pa-
tients with CSK or PTEN mutation might therefore be
good candidates for combinational therapy with lapati-
nib, PI3K inhibitor and MEK inhibitor. To explore the
potential clinical application, we checked the status of
PTEN or CSK mutations in the HER2-amplified GC
cases. For this purpose, we collected the variants data
from over 630 GC patient samples from the public re-
source (cBioPotal) [41], and 103 GC patient samples
from our previous study [27]. Over 23% of GC patients
showed HER2 amplification in the public samples. Ap-
proximately 14% of GC patients harbored HER2 amplifi-
cation in our dataset. 3–14% of the GC patients with
HER2 amplification have either PTEN or CSK mutations
in the genome (Table S5). Of note, the public cohort
data is only based on somatic mutations and this per-
centage could be higher if we include germline muta-
tions. In addition, GC patients with HER2 amplification
and gene alterations associated with PI3K or MAPK
pathways could also benefit from this treatment strategy.
These gene alterations include but not limited to
PIK3CA, PIK3CB, EGFR, KRAS, BRAF and MLK3. For
example, gain of function mutations in PIK3CA have
been suggested to be associated with trastuzumab/lapati-
nib resistance by up-regulating PI3K pathway in breast
cancer [42, 43].
In this study, we also identified and validated other
genes that may be involved in lapatinib resistance,
such as NF1 and KEAP1 (Fig. S2 and Fig. S3). Inter-
estingly, we found that lapatinib in combination with
PI3K inhibitor copanlisib and MEK inhibitor trameti-
nib could also overcome the resistance to lapatinib
conferred by NF1 and KEAP1 knockout (Fig. S4D).
Although the mechanism is not elucidated in GC, loss
of NF1 has been associated with resistance to EGFR
TKIs in lung adenocarcinomas and resistance to
BRAF inhibitor in melanoma by increasing MAPK
and/or PI3K signaling via negatively regulating Ras
[44, 45]. Previous studies suggest that loss of KEAP1
function may lead to the nuclear translocation of
Nrf2 and subsequent increased expression of cellular
antioxidants and xenobiotic detoxification enzymes,
which may be the major resistance mechanism of
tumor cells against chemotherapeutic drugs [46, 47].
Coincidentally, Nrf2 activation caused by loss of
KEAP1 could be blocked by PI3K inhibitor [48],
which is consistent with our result of the combin-
ational treatment on KEAP1 null GC cells. Taken to-
gether, PI3K and MAPK signaling may also play
important roles in lapatinib resistance in the HER2-
amplified GC patients bearing loss of function muta-
tions of NF1 or KEAP1. Merging our finding with
previous studies, we draw a schematic diagram show-
ing potential HER2-related signaling pathways and ac-
tion mechanisms of various inhibitors in HER2-
amplified GC (Fig. 6). Additional studies would be
helpful to elucidate the molecular mechanisms of the
drug resistance induced by these gene mutations.
In summary, CRISPR library screening provides a valu-
able platform for gene function screening and novel
drug target discovery. Our study has validated the ap-
proach and revealed the potential molecular mechanisms
for the treatment of subsets of GC cases: loss-of-
function mutation of CSK or PTEN causes resistance to
lapatinib in HER2-amplified GC cells via hyperactivation
of PI3K and MAPK pathways, which can be overcome
by applying drug combination of lapatinib, PI3K and
MAPK pathway inhibitors. The current study extends
the understanding of lapatinib resistance in HER2-
amplified GC, which would facilitate to develop alterna-
tive treatment strategy to increase efficacy of anti-HER2
treatment. To further confirm the efficacy of this new
therapeutic strategy pre-clinically, a patient-derived
xenograft (PDX) model-based study is expected in the
near future.
Conclusions
This study provides insights into understanding of the
resistance mechanism of HER2 targeted therapy, that
loss of function mutation of CSK and PTEN re-activate
PI3K and MAPK pathways and substantially cause lapa-
tinib resistance. And we developed the novel strategy
targeting both PI3K and MAPK pathways that may ul-
timately overcome resistance or limited efficacy of lapa-
tinib treatment for a subset of HER2-amplified GC
cases.
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Additional file 1: Fig. S1. (A) CRISPR-Cas9 library sequencing data
analysis workflow. (B) The distribution of sgRNA frequencies of the
corresponding replicates of N87 and OE19 cells. (C) Comparison of
different treatment conditions and biological replicates in the N87 and
OE19 lapatinib screening. Each square in the lower left half of the matrix
compares the normalized sgRNA read count between two biological
samples. Sample labels for each axis are indicated on the diagonal. For
the sample labels, N87 and OE19 are the cell line names; D14 means
vehicle day 14 and L14 means lapatinib treated day 14. The last number
1 or 2 means the replicates. The Pearson correlation coefficient can be
found in each square in the upper right half of the matrix. For example,
the number 0.947 on the second row of top row indicates that the
correlation coefficient between N87 vehicle day replicate 1 and replicate
2 is 0.947. Wilcoxon rank-sum test indicated the following, **significant
difference from the control, p < 2.2e-16. Fig. S2. Validation of the screen
that disruption of a few other candidate genes individually in GC cell
lines causes resistance to lapatinib. (A) Cell viability curve of KEAP1, BAX,
MED24 or TADA1 knockout OE19 cells treated with indicated doses of
lapatinib, respectively. OE19 cells were transduced with lentivirus carrying
sgRNAs targeting the indicated gene individually. The drug resistance of
gene knockout and the control cells were measured by the relative per-
centage of cell viability. (B) Cell viability curve of KCTD5 or NF1 knockout
OE19 cells treated with indicated doses of lapatinib, respectively. OE19
cells were transduced with lentivirus carrying sgRNAs targeting the indi-
cated gene individually. The drug resistance of gene knockout and the
control cells were examined by the relative percentage of cell viability.
Unpaired Student’s t test indicated the following: *significant difference
from the control, p < 0.05; **significant difference from the control, p <
0.01. Fig. S3. Protein interaction networks and the predicted partners
were analyzed by STRING on the validated genes. CSK, PTEN, KEAP1, BAX,
MED24, TADA1, KCTD5, NF1 (validated genes) and HER2 (ERBB2) were
mapped by searching the STRING for Protein interaction networks (A)
and the predicted partners analysis (B). In the resulting protein associ-
ation network, proteins are presented as nodes which are connected by
lines whose thickness represents the confidence level. (C) Heatmap of
139 DEGs between CSK null cells vs parental N87 cells (Fold change > 1.5.
FDR < 0.1). (D) Heatmap of 997 DEGs between PTEN null cells vs parental
OE19 cells (Fold change > 1.5. FDR < 0.1). Fig. S4. Pharmacological test
with trastuzumab, LY294002 and combination of lapatinib, trametinib
and/or copanlisib on lapatinib resistant GC cells. (A) Growth curve of test
groups of N87 cells with 0.01 μM lapatinib in combination with indicated
doses of trastuzumab for 6 days. (B) Growth curve of CSK and PTEN gene
knockout OE19 cell lines treated with 0.05 μM lapatinib in combination
with different doses of PI3K inhibitor LY294002 for 6 days. OE19 cells
transduced with non-targeting sgRNA as control. (C) Pharmacological in-
hibition of PI3K, MAPK signaling pathway re-sensitizes CSK or PTEN null
GC cells to lapatinib. Inhibition effect of 0.01 μM lapatinib alone or in
combination with 0.1 μM trametinib or /and 0.1 μM copanlisib for 6 days.
N87 cells transduced with CSK targeting sgRNAs or PTEN targeting
sgRNAs were used for the test. N87 cells transduced with non-targeting
sgRNA as control. (D) Pharmacological inhibition of PI3K, MAPK signaling
pathway re-sensitizes NF1 or KEAP1 null GC cells to lapatinib. Inhibition
effect of 0.05 μM lapatinib alone or in combination with 0.1 μM trameti-
nib or /and 0.1 μM copanlisib for 6 days. OE19 cells transduced with NF1
targeting sgRNAs or KEAP1 targeting sgRNAs were used for the test.
OE19 cells transduced with non-targeting sgRNA as control. Unpaired
Student’s t test indicated the following: *significant difference from the
control, p < 0.05; **significant difference from the control, p < 0.01. Fig.
S5. Lapatinib response curve of N87-WT, N87-CSK−/− or N87-PTEN−/−
xenograft tumors. Lapatinib at concentration of 50 mg/kg, 100 mg/kg
and 200 mg/kg were given to xenografts bearing N87-WT (A), N87-
CSK−/− (B) or N87-PTEN−/− (C) tumor by oral gavage. Tumor sizes were
measured twice a week.
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